Literature DB >> 6460516

Relative potency and structure activity relationships of aldosterone antagonists in healthy man: correlation with animal experience.

G T McInnes, J R Shelton, L E Ramsay, I R Harrison, M J Asbury, J M Clarke, R M Perkins, G R Venning.   

Abstract

1 The renal antimineralocorticoid potency of single doses of thirteen compounds with properties in animals compatible with competitive aldosterone antagonism was compared to that of spironolactone in healthy men. 2 Twelve compounds showed significant activity when compared to placebo but only one, prorenoate potassium, was significantly more potent than spironolactone on a weight basis. 3 The results allowed ranking of the compounds in order of potency relative to spironolactone and general observations on structure activity relationships in man. 4 Animal bioassays and in vitro aldosterone binding studies are unreliable predictors of the human activity of competitive mineralocorticoid antagonists.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6460516      PMCID: PMC1402118          DOI: 10.1111/j.1365-2125.1982.tb01383.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  Screening for anti-hormones by receptor studies.

Authors:  J P Raynaud; C Bonne; M M Bouton; M Moguilewsky; D Philibert; G Azadian-Boulanger
Journal:  J Steroid Biochem       Date:  1975-05       Impact factor: 4.292

2.  Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses.

Authors:  L E Ramsay; P Hessian; M J Tidd
Journal:  Br J Clin Pharmacol       Date:  1975-06       Impact factor: 4.335

3.  Antagonism of spironolactone-induced natriuresis by aspirin in man.

Authors:  M G Tweeddale; R I Ogilvie
Journal:  N Engl J Med       Date:  1973-07-26       Impact factor: 91.245

4.  Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors.

Authors:  J W Funder; D Feldman; E Highland; I S Edelman
Journal:  Biochem Pharmacol       Date:  1974-05-15       Impact factor: 5.858

5.  Relative potency of prorenoate and spironolactone in normal man.

Authors:  L Ramsay; I Harrison; J Shelton; M Tidd
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

6.  7alpha-Carboalkoxy steroidal spirolactones as aldosterone antagonists.

Authors:  R M Weier; L M Hofmann
Journal:  J Med Chem       Date:  1975-08       Impact factor: 7.446

7.  Potassium prorenoate: a new steroidal aldosterone antagonist.

Authors:  L M Hofmann; L J Chinn; H A Pedrera; M I Krupnick; O D Suleymanov
Journal:  J Pharmacol Exp Ther       Date:  1975-08       Impact factor: 4.030

8.  Spironolactone and potassium canrenoate in normal man.

Authors:  L Ramsay; J Shelton; I Harrison; M Tidd; M Asbury
Journal:  Clin Pharmacol Ther       Date:  1976-08       Impact factor: 6.875

9.  Mineralocorticoid receptors in human kidney.

Authors:  D T Matulich; B J Spindler; M Schambelan; J D Baxter
Journal:  J Clin Endocrinol Metab       Date:  1976-11       Impact factor: 5.958

10.  Agonist and antimineralocorticoid activities of spirolactones.

Authors:  C Sakauye; D Feldman
Journal:  Am J Physiol       Date:  1976-07
View more
  1 in total

1.  Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial.

Authors:  Simon de Denus; Grégoire Leclair; Marie-Pierre Dubé; Isabelle St-Jean; Yassamin Feroz Zada; Essaïd Oussaïd; Martin Jutras; Michael M Givertz; Robert J Mentz; W H Wilson Tang; João Pedro Ferreira; Jean Rouleau; Javed Butler; Andreas P Kalogeropoulos
Journal:  Eur J Heart Fail       Date:  2020-04-01       Impact factor: 15.534

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.